Juanita Garza
Family · Harlingen, TXNPI 1801432232
Payments from drug & device makers
Across 157 payments — averaging $14.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$672
- AbbVie$265
- Novo Nordisk$243
- Astellas Pharma US Inc$130
- Bayer$118
- Sanofi-aventis U.S. LLC$113
- plus $670 from 17 others
What the payments were for
- Food & beverage$2,211100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 67 | $672 |
| AbbVie | 14 | $265 |
| Novo Nordisk | 19 | $243 |
| Astellas Pharma US Inc | 9 | $130 |
| Bayer | 6 | $118 |
| Sanofi-aventis U.S. LLC | 7 | $113 |
| Boehringer Ingelheim | 4 | $87 |
| Amgen(2 entities) | 4 | $70 |
| GSK | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Pfizer | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Exact Sciences | 2 | $42 |
| Phadia US Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $33 |
| Madrigal Pharmaceuticals | 1 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| AstraZeneca | 2 | $27 |
| Lundbeck LLC | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Si-bone, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$2,211 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $99,560 |
| JardianceEmpagliflozin | 69 | $63,929 |
| OzempicSemaglutide | 29 | $41,751 |
| FarxigaDapagliflozin Propanediol | 39 | $34,438 |
| LinzessLinaclotide | 27 | $26,466 |
| TrulicityDulaglutide | 17 | $25,064 |
| EliquisApixaban | 14 | $20,238 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $18,002 |
| JanuviaSitagliptin Phosphate | 13 | $15,027 |
| MyrbetriqMirabegron | 13 | $12,552 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,591 |
| TradjentaLinagliptin | 16 | $9,750 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $5,364 |
| Rosuvastatin Calcium | 178 | $2,253 |
| Atorvastatin Calcium | 195 | $1,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $672 | $124,62481 claims |
| Boehringer IngelheimJardiance, Tradjenta | $87 | $73,67985 claims |
| Novo NordiskOzempic | $243 | $41,75129 claims |
| AstraZenecaFarxiga | $27 | $34,43839 claims |
| AbbVieLinzess | $265 | $26,46627 claims |
| PfizerEliquis | $49 | $20,23814 claims |
| Astellas Pharma US IncMyrbetriq | $130 | $12,55213 claims |
| GSKTrelegy Ellipta | $64 | $11,59112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.
Other family in Harlingen
- Laura SaucedoHarlingen$44K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.